KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2
- PMID: 39919777
- PMCID: PMC12181982
- DOI: 10.1016/S1473-3099(25)00058-1
KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2
References
-
- FDA. FDA approves and authorizes updated mRNA COVID-19 vaccines to better protect against currently circulating variants. Aug 22, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-and-aut... (accessed Nov 28, 2024).
-
- European Medicines Agency. COVID-19 medicines. 2024. https://www.ema.europa.eu/en/human-regulatory-overview/public-health-thr... (accessed Nov 28, 2024).
-
- GOV.UK. MHRA approves Comirnaty KP.2 COVID-19 vaccine for adults. Oct 10, 2024. https://www.gov.uk/government/news/mhra-approves-comirnaty-kp2-covid-19-... (accessed Nov 28, 2024).
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
